Results 111 to 120 of about 983,540 (218)

Safety and Immunogenicity of SARS-CoV-2 vaccines in people with HIV [PDF]

, 2022
Concise communication[Abstract] Objective: To evaluate the safety and the serological response after two doses of mRNA-based SARS-CoV-2 vaccination in people with HIV (PWH).
Bou, Germán, Castro-Iglesias, Ángeles, Cañizares, Angelina, González de Aledo, Manuel, López, Soledad, Mena, Álvaro, Miguez, Enrique, Moldes, Luz, Vázquez-Rodríguez, Pilar   +8 more
core   +1 more source

Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection

Science Translational Medicine, 2021
Deep mutational scanning shows that the mRNA-1273 RBD-binding antibody response is less affected by single viral mutations than the infection response.
Allison J. Greaney, Andrea N. Loes, Lauren E. Gentles, K. H. Crawford, Tyler N. Starr, Keara D. Malone, H. Chu, J. Bloom   +7 more
semanticscholar   +1 more source

Comparison of immune activation of the COVID vaccines : ChAdOx1, BNT162b2, mRNA-1273, BBIBP-CorV, and Gam-COVID-Vac from serological human samples in Hungary showed higher protection after mRNA-based [PDF]

, 2022
To gain insight into the different protective mechanisms of approved vaccines, this study focuses on the comparison of humoral and cellular immune responses of five widely used vaccines including ChAdOx1 (AZD1222, AstraZeneca), BNT162b2 (Pfizer), mRNA ...
Bukva Mátyás, Fodor Eszter, Földes Fanni Vivien, Hamar E, Hetényi Roland, Hinsenkamp Adél Gyöngyvér, Hornyák István, Jakab Ferenc, Kemenesi Gábor, Kuten-Pella O, Lacza Zsombor, Madár Á, Olmos Calvo I, Zana Brigitta   +13 more
core   +1 more source

Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial

medRxiv, 2021
Background: In the Coronavirus Efficacy (COVE) trial, estimated mRNA-1273 vaccine efficacy against coronavirus disease-19 (COVID-19) was 94%. SARS-CoV-2 antibody measurements were assessed as correlates of COVID-19 risk and as correlates of protection ...
P. Gilbert, D. Montefiori, A. McDermott, Y. Fong, David C. Benkeser, Wei-zhi Deng, Honghong Zhou, Christopher R. Houchens, Karen A. Martins, L. Jayashankar, F. Castellino, B. Flach, Bob C. Lin, S. O'connell, C. McDanal, Amanda Eaton, M. Sarzotti-Kelsoe, Yiwen Lu, Chenchen Yu, Bhavesh Borate, Lars van der Laan, N. Hejazi, C. Huynh, Jacqueline M. Miller, Hana M. El Sahly, L. Baden, Mira Baron, Luis I. De La Cruz, C. Gay, S. Kalams, Colleen F. Kelley, M. Kutner, M. Andrasik, J. Kublin, L. Corey, K. Neuzil, Lindsay N. Carpp, R. Pajon, D. Follmann, R. Donis, R. Koup   +40 more
semanticscholar   +1 more source

mRNA-1273 bivalent (original and Omicron) COVID-19 vaccine effectiveness against COVID-19 outcomes in the United States

Nature Communications, 2023
The bivalent (original and Omicron BA.4/BA.5) mRNA-1273 COVID-19 vaccine was authorized to offer broader protection against COVID-19. We conducted a matched cohort study to evaluate the effectiveness of the bivalent vaccine in preventing hospitalization ...
H. Tseng, B. Ackerson, L. Sy, J. Tubert, Yi Luo, S. Qiu, Gina S. Lee, K. Bruxvoort, J. Ku, A. Florea, H. Takhar, R. Bathala, Cindy Ke Zhou, Daina B Esposito, Morgan A. Marks, Evan J. Anderson, C. Talarico, L. Qian   +17 more
semanticscholar   +1 more source

Heterologous COVID-19 Booster Vaccination in the Chronic Disorder of Consciousness: A Pilot Study

Clinics and Practice, 2022
Significant anti-spike protein receptor-binding domain (S-RBD) antibody responses have been demonstrated in patients with chronic disorder of consciousness (DOC) completing a COVID-19 vaccine regime with BNT162b2 (Pfizer–BioNTech). We now provide further
Maria Elena Pugliese, Riccardo Battaglia, Maria Girolama Raso, Raffaela Chiaravalloti, Francesco Coschignano, Angela Pagliuso, Roberta Bruschetta, Giovanni Pugliese, Paolo Scola, Paolo Tonin, Antonio Cerasa   +10 more
doaj   +1 more source

Risk factors for SARS-CoV-2 infection after primary vaccination with ChAdOx1 nCoV-19 or BNT1262b2 and after booster vaccination with BNT1262b2 or mRNA-1273: a population-based cohort study (COVIDENCE UK) [PDF]

, 2022
Giulia Vivaldi, David A. Jolliffe, Hayley Holt, Florence Tydeman, Mohammad Talaei, Gwyneth A. Davies, Ronan A Lyons, Chris Griffiths, Frank Kee, Aziz Sheikh, Seif O. Shaheen, Adrian R. Martineau   +11 more
openalex   +1 more source

Determinants of antibody responses to two doses of ChAdOx1 nCoV-19 or BNT162b2 and a subsequent booster dose of BNT162b2 or mRNA-1273: population-based cohort study (COVIDENCE UK) [PDF]

, 2022
David A. Jolliffe, Sian Faustini, Hayley Holt, Natalia Perdek, Sheena Maltby, Mohammad Talaei, Matthew Greenig, Giulia Vivaldi, Florence Tydeman, Jane Symons, Gwyneth A. Davies, Ronan A Lyons, Chris Griffiths, Frank Kee, Aziz Sheikh, Seif O. Shaheen, Alex Richter, Adrian R. Martineau   +17 more
openalex   +1 more source

Time and cost of administering COVID-19 mRNA vaccines in the United States

Human Vaccines & Immunotherapeutics, 2021
In early 2020, the World Health Organization (WHO) declared the coronavirus disease 2019 (COVID-19) outbreak a global pandemic. In response, two novel messenger RNA (mRNA)-based vaccines: mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) were rapidly ...
Benjamin Yarnoff, Steven Bodhaine, Ed Cohen, Philip O. Buck   +3 more
doaj   +1 more source

A review of the immunogenicity and safety of booster doses of omicron variant-containing mRNA-1273 COVID-19 vaccines in adults and children

Expert Review of Vaccines
Introduction Vaccination against SARS-CoV-2 is an integral pillar of the public health approach to COVID-19. With the emergence of variants of concern that increase transmissibility and escape from vaccine- or infection-induced protection, vaccines have ...
Frances Priddy, Spyros Chalkias, Brandon Essink, Jordan Whatley, Adam Brosz, Ivan T. Lee, Jing Feng, LaRee Tracy, Weiping Deng, Wen Zhou, Honghong Zhou, Avika Dixit, Sabine Schnyder Ghamloush, Bethany Girard, Elizabeth de Windt, Anne Yeakey, Jacqueline Miller, Rituparna Das, Barbara J. Kuter   +18 more
doaj   +1 more source